Scholarlink

Background <p>Adjuvant pembrolizumab decreases the risk of recurrence and prolongs survival after surgery for high-risk clear cell renal cell carcinoma. Cost-effectiveness analyses evaluate therapy associated risks, toxicity, quality of life, costs of therapies and follow-up regimens and represent an essential adjunct for the evaluation of new therapies. At present, there is no cost effectiveness analysis for adjuvant pembrolizumab within the German healthcare system.</p> Methods <p>A&#xa0;Markov model was used to evaluate cost-effectiveness. The impact of variables on the cost-effectiveness of therapy were investigated with one-way deterministic and probabilistic sensitivity analysis and thresholds were determined.</p> Results <p>The adjuvant treatment with pembrolizumab was cost-effective over a&#xa0;5-year period, with an ICER (incremental cost-effectiveness ratio) of 68,278 €/QALY (quality-adjusted life year) assuming a&#xa0;WTP (willingness to pay) threshold of 100,000 €/QALY.</p> Conclusion <p>Adjuvant treatment in high-risk patients with pembrolizumab has been shown to be cost-effective when applied within the German health system. It should therefore be offered to all patients with an increased risk for recurrence after curative surgery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adjuvante Immuntherapie mit Pembrolizumab beim Nierenzellkarzinom – ist der neue Therapiestandard auch kosteneffektiv?

  • 期刊论文

  • 发表日期：

    2025年7月10日

查看全文
  • Sarah Katharina Assiba Weiß,
  • Carsten Lange,
  • Nicole Hübscher,
  • Abdullah Al Hasan,
  • Steffen Hallmann,
  • Tobias Klatte

摘要

Background

Adjuvant pembrolizumab decreases the risk of recurrence and prolongs survival after surgery for high-risk clear cell renal cell carcinoma. Cost-effectiveness analyses evaluate therapy associated risks, toxicity, quality of life, costs of therapies and follow-up regimens and represent an essential adjunct for the evaluation of new therapies. At present, there is no cost effectiveness analysis for adjuvant pembrolizumab within the German healthcare system.

Methods

A Markov model was used to evaluate cost-effectiveness. The impact of variables on the cost-effectiveness of therapy were investigated with one-way deterministic and probabilistic sensitivity analysis and thresholds were determined.

Results

The adjuvant treatment with pembrolizumab was cost-effective over a 5-year period, with an ICER (incremental cost-effectiveness ratio) of 68,278 €/QALY (quality-adjusted life year) assuming a WTP (willingness to pay) threshold of 100,000 €/QALY.

Conclusion

Adjuvant treatment in high-risk patients with pembrolizumab has been shown to be cost-effective when applied within the German health system. It should therefore be offered to all patients with an increased risk for recurrence after curative surgery.